Biotechnology Industry Trademark Agreements

Fifth Amendment to Trademark License and Supply Agreement dated as of September 30, 2020, between the Company and Mission Pharmacal Company (Retrophin, Inc., Filed With SEC on February 20, 2024)

Amendment Two to the Third Amendment to Trademark License and Supply Agreement, dated November 3, 2017, by and between the Company and Mission Pharmacal Company (Retrophin, Inc., Filed With SEC on February 20, 2024)

Amendment One to the Third Amendment to Trademark License and Supply Agreement, dated September 12, 2016, by and between the Company and Mission Pharmacal Company (Retrophin, Inc., Filed With SEC on February 20, 2024)

Third Amendment to Trademark License and Supply Agreement dated as of March 17, 2016, between the Company and Mission Pharmacal Company (Retrophin, Inc., Filed With SEC on February 20, 2024)

Trademark License and Supply Agreement, dated May 29, 2014, by and between the Company and Mission Pharmacal Company (Retrophin, Inc., Filed With SEC on February 20, 2024)

Sublicense Agreement dated as of December 7, 2012 between Biostage, Inc. and Harvard Bioscience, Inc., and related Trademark License Agreement, dated December 19, 2002, by and... (Biostage, Inc., Filed With SEC on March 7, 2023)

Master Trademark Assignment Agreement, dated May 5, 2022, by and among ICPT Inc., RXF Technologies, Inc. and Mercury Pharma (INTERCEPT PHARMACEUTICALS, INC., Filed With SEC on August 3, 2022)

Official USPTO Notice of Publication under 12(A) for the Trademark ProLectin (BIOXYTRAN, INC, Filed With SEC on June 10, 2022)

BioXcel Trademark License Agreement, between the Company and BioXcel LLC, dated April 9, 2022 (BioXcel Therapeutics, Inc., Filed With SEC on May 9, 2022)

Fifth Amendment to Trademark License and Supply Agreement, effective September 30, 2020, between the Company and Mission Pharmacal Company (Retrophin, Inc., Filed With SEC on November 5, 2020)

Fourth Amendment to Trademark License and Supply Agreement dated as of November 28, 2018, between Retrophin Inc. and Mission Pharmacal (Retrophin, Inc., Filed With SEC on February 26, 2019)

Amended and Restated Trademark License Agreement, dated September 28, 2017, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc (Aptevo Therapeutics Inc., Filed With SEC on March 13, 2018)

Amendment Two to the Third Amendment to Trademark License and Supply Agreement, dated November 3, 2017, by and between the Company and Mission Pharmacal Company (Retrophin, Inc., Filed With SEC on February 27, 2018)

AMENDMENT ONE TO THE THIRD AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT (Retrophin, Inc., Filed With SEC on November 4, 2016)

TRADEMARK LICENSE AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF JULY 29, 2016 TRADEMARK LICENSE AGREEMENT (Aptevo Therapeutics Inc., Filed With SEC on August 2, 2016)

THIRD AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT (Retrophin, Inc., Filed With SEC on May 5, 2016)

SECOND AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT (Retrophin, Inc., Filed With SEC on May 5, 2016)

FIRST AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT (Retrophin, Inc., Filed With SEC on July 29, 2014)

Trademark License & Supply Agreement (Retrophin, Inc., Filed With SEC on June 4, 2014)

Trademark License Agreement between MiMedx, Inc. and SaluMedica, LLC, dated March 31, 2008 (MiMedx Group, Inc., Filed With SEC on April 4, 2008)

TRADEMARK LICENSE AGREEMENT (MiMedx Group, Inc., Filed With SEC on February 8, 2008)

PATENT, TRADEMARK (NAVIDEA BIOPHARMACEUTICALS, INC., Filed With SEC on January 2, 2008)

AGREEMENT RELATING TO ADDITIONAL TRADEMARK (Acorda Therapeutics, Filed With SEC on October 5, 2005)

TRADEMARK LICENSE AGREEMENT (Acorda Therapeutics, Filed With SEC on October 5, 2005)

Category

Industry

Companies

Contracts

Trademark Agreements in the Biotechnology Industry